Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy PA Beavis, MA Henderson, L Giuffrida, JK Mills, K Sek, RS Cross, ... The Journal of clinical investigation 127 (3), 929-941, 2017 | 293 | 2017 |
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity AJ Davenport, RS Cross, KA Watson, Y Liao, W Shi, HM Prince, ... Proceedings of the National Academy of Sciences 115 (9), E2068-E2076, 2018 | 270 | 2018 |
Functional and molecular characterisation of EO771. LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer CN Johnstone, YE Smith, Y Cao, AD Burrows, RSN Cross, X Ling, ... Disease models & mechanisms 8 (3), 237-251, 2015 | 269 | 2015 |
CAR-T cells inflict sequential killing of multiple tumor target cells AJ Davenport, MR Jenkins, RS Cross, CS Yong, HM Prince, DS Ritchie, ... Cancer immunology research 3 (5), 483-494, 2015 | 127 | 2015 |
MYB Is Essential for Mammary Tumorigenesis R Yu Miao, Y Drabsch, RS Cross, D Cheasley, S Carpinteri, L Pereira, ... Cancer research 71 (22), 7029-7037, 2011 | 72 | 2011 |
Finding the keys to the CAR: identifying novel target antigens for T cell redirection immunotherapies RC Abbott, RS Cross, MR Jenkins International Journal of Molecular Sciences 21 (2), 515, 2020 | 58 | 2020 |
Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein RS Cross, J Malaterre, AJ Davenport, S Carpinteri, RL Anderson, ... Clinical & translational immunology 4 (1), e30, 2015 | 51 | 2015 |
The evolving protein engineering in the design of chimeric antigen receptor T cells HE Hughes-Parry, RS Cross, MR Jenkins International Journal of Molecular Sciences 21 (1), 204, 2019 | 38 | 2019 |
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma RC Abbott, DJ Verdon, FM Gracey, HE Hughes‐Parry, M Iliopoulos, ... Clinical & translational immunology 10 (5), e1283, 2021 | 31 | 2021 |
De novo-designed transmembrane domains tune engineered receptor functions A Elazar, NJ Chandler, AS Davey, JY Weinstein, JV Nguyen, R Trenker, ... Elife 11, e75660, 2022 | 29 | 2022 |
BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells D Moujalled, AG Southon, E Saleh, K Brinkmann, F Ke, M Iliopoulos, ... Cell Death & Differentiation 29 (7), 1335-1348, 2022 | 18 | 2022 |
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer R Millen, J Malaterre, RS Cross, S Carpinteri, J Desai, B Tran, P Darcy, ... Oncoimmunology 5 (7), e1149667, 2016 | 16 | 2016 |
Hsp70 architecture: the formation of novel polymeric structures of Hsp70. 1 and Hsc70 after proteotoxic stress R Steel, RS Cross, SL Ellis, RL Anderson PLoS One 7 (12), e52351, 2012 | 13 | 2012 |
MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms LH Chi, RSN Cross, RP Redvers, M Davis, S Hediyeh-Zadeh, ... Oncogenesis 11 (1), 38, 2022 | 11 | 2022 |
Myb via TGF β is required for collagen type 1 production and skin integrity S Sampurno, R Cross, H Pearson, P Kaur, J Malaterre, RG Ramsay Growth Factors 33 (2), 102-112, 2015 | 6 | 2015 |
HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma SS Wang, AJ Davenport, M Iliopoulos, HE Hughes-Parry, KA Watson, ... Neuro-Oncology Advances 5 (1), vdad024, 2023 | 5 | 2023 |
A novel peptide-MHC targeted chimeric antigen receptor T cell forms a T cell-like immune synapse SS Wang, K Luong, FM Gracey, S Jabar, B McColl, RS Cross, MR Jenkins Biomedicines 9 (12), 1875, 2021 | 5 | 2021 |
Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma RC Abbott, M Iliopoulos, KA Watson, V Arcucci, M Go, HE Hughes‐Parry, ... Clinical & Translational Immunology 12 (3), e1440, 2023 | 4 | 2023 |
Bigger, stronger, faster: chimeric antigen receptor T cells are olympic killers PJ Neeson, AJ Davenport, JA Trapani, M Kershaw, R Cross, HM Prince, ... Blood 128 (22), 814, 2016 | 3 | 2016 |
Endogenous H3. 3K27M derived peptide restricted to HLA-A∗ 02: 01 is insufficient for immune-targeting in diffuse midline glioma SS Wang, K Pandey, KA Watson, RC Abbott, NA Mifsud, FM Gracey, ... Molecular Therapy-Oncolytics 30, 167-180, 2023 | 2 | 2023 |